No abstract

Organismal aging is driven by interconnected molecular changes encompassing internal and extracellular factors. Combinational analysis of high-throughput ‘multi-omics’ datasets (gathering information from genomics, epigenomics, transcriptomics, proteomics, metabolomics and pharmacogenomics), at either populational or single-cell levels, can provide a multi-dimensional, integrated profile of the heterogeneous aging process with unprecedented throughput and detail. These new strategies allow for the exploration of the molecular profile and regulatory status of gene expression during aging, and in turn, facilitate the development of new aging interventions. With a continually growing volume of valuable aging-related data, it is necessary to establish an open and integrated database to support a wide spectrum of aging research. The Aging Atlas database aims to provide a wide range of life science researchers with valuable resources that allow access to a large-scale of gene expression and regulation datasets created by various high-throughput omics technologies. The current implementation includes five modules: transcriptomics (RNA-seq), single-cell transcriptomics (scRNA-seq), epigenomics (ChIP-seq), proteomics (protein–protein interaction), and pharmacogenomics (geroprotective compounds). Aging Atlas provides user-friendly functionalities to explore age-related changes in gene expression, as well as raw data download services. Aging Atlas is freely available at https://bigd.big.ac.cn/aging/index.

Introduction: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). However, the efficacy of standard subsequent therapies after CDK4/6i-based treatment is unclear. This study aimed to examine physician practice patterns and treatment outcomes of subsequent therapies administered after progression on palbociclib therapy in clinical practice. Methods: The study included 200 patients with HR+/HER2– MBC who underwent subsequent treatments after progressing on palbociclib-based regimens in five Chinese institutions between August 2017 and April 2020. The treatment pattern, progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were reported. Results: A total of 200 patients were included, of whom 147 (73.5%) and 53 (26.5%) received subsequent chemotherapy and endocrine therapy, respectively. The frequently used monochemotherapy regimens were taxane ( n = 29), capecitabine ( n = 21), and vinorelbine ( n = 17), while the endocrine therapy regimens were chidamide plus exemestane ( n = 16) and everolimus plus exemestane ( n = 9). The overall median PFS (mPFS) was 5.5 months, with no significant difference in mPFS between the chemotherapy and endocrine therapy groups ( p = 0.669). However, among patients not sensitive to prior palbociclib treatment, those administered chemotherapy had significantly longer PFS than those administered endocrine therapy ( p = 0.006). The mPFS with endocrine therapy after first-, second-, and subsequent-line palbociclib was 13.4, 3.1, and 4.1 months, respectively ( p = 0.233); in contrast, the mPFS with chemotherapy was 7.2, 6.5, and 4.9 months after first-, second-, and subsequent-line palbociclib, respectively ( p = 0.364). The median OS was not achieved. The ORR was 10.6% among the 198 patients included in the analysis. Conclusions: Physicians prefer chemotherapy over endocrine therapy for the treatment of patients with HR+/HER2– MBC who develop progression on palbociclib. Sensitivity to previous palbociclib treatment might be one of the indicators for predicting response to subsequent treatment. ClinicalTrials.gov identifier: NCT04517318

No abstract

No abstract

In 2014, Chen et al. proposed a one-way hash self-healing group key distribution scheme for resource-constrained wireless networks in the journal of Sensors (14(14):24358-24380, doi: 10.3390/s141224358). They asserted that their Scheme 2 achieves mt-revocation capability, mt-wise forward secrecy, any-wise backward secrecy and has mt-wise collusion attack resistance capability. Unfortunately, this paper pointed out that their scheme does not satisfy the forward security, mt-revocation capability and mt-wise collusion attack resistance capability.

No abstract

In resource-constrained wireless networks, resources such as storage space and communication bandwidth are limited. To guarantee secure communication in resource-constrained wireless networks, group keys should be distributed to users. The self-healing group key distribution (SGKD) scheme is a promising cryptographic tool, which can be used to distribute and update the group key for the secure group communication over unreliable wireless networks. Among all known SGKD schemes, exponential arithmetic based SGKD (E-SGKD) schemes reduce the storage overhead to constant, thus is suitable for the the resource-constrained wireless networks. In this paper, we provide a new mechanism to achieve E-SGKD schemes with backward secrecy. We first propose a basic E-SGKD scheme based on a known polynomial-based SGKD, where it has optimal storage overhead while having no backward secrecy. To obtain the backward secrecy and reduce the communication overhead, we introduce a novel approach for message broadcasting and self-healing. Compared with other E-SGKD schemes, our new E-SGKD scheme has the optimal storage overhead, high communication efficiency and satisfactory security. The simulation results in Zigbee-based networks show that the proposed scheme is suitable for the resource-restrained wireless networks. Finally, we show the application of our proposed scheme.